Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
10 stocks we like better than Travere Therapeutics › The stock of commercial-stage biotech Travere Therapeutics (NASDAQ: TVTX) barreled into the late holiday period in style. On a pair of new analyst notes covering the company, investors piled into its shares to leave them with an almost 14% gain on Hump Day. The first of those two updates was authored by Jefferies 's Maury Raycroft. He flagged five biotechs as being particularly juicy takeover candidates in 2026, and Travere made the list. The pundit singled out the company's Filspari as being a choice asset, writing that it could be a blockbuster drug for its developer. The drug has been submitted for approval by the U.S. Food and Drug Administration (FDA) for the treatment of focal segmental glomerulosclerosis (FSGS), a kidney disorder. The regulator set Jan. 13, 2026, as the deadline for its decision. In early 2024, Travere won full approval from the American regulator for Filspari to treat another kidney affliction, immu
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? [Yahoo! Finance]Yahoo! Finance
- Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Analyst Actions
- 11/28/25 - HC Wainwright
TVTX
Sec Filings
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- 12/3/25 - Form 4
- TVTX's page on the SEC website